Drug Developer Geno Ditches IPO Amid Rocky Biotech Market
Massachusetts-based Geno LLC, an early-stage pharmaceutical developer focused on treatments for cardiac and pulmonary diseases, abandoned plans Tuesday for an initial public offering, as the biotech IPO market continues to waver...To view the full article, register now.
Already a subscriber? Click here to view full article